Aquestive Therapeutics was Zevra Therapeutics’s largest product and service line in fiscal 2021, bringing in $20.90M of $28.60M (73%).
| Product and Service | FY 2021 |
|---|---|
| Aquestive Therapeutics | $20.90M |
| Corium, Inc | $7.70M |
| Total | $28.60M |
Zevra Therapeutics brought in $28.60M from its two product and service lines in fiscal 2021, the year ended December 31, 2021. Aquestive Therapeutics was the largest at $20.90M (73.1%), ahead of Corium, Inc at $7.70M (26.9%).
License was Zevra Therapeutics’s largest product and service line in fiscal 2021, bringing in $20.90M of $28.60M (73%).
| Product and Service | FY 2021 |
|---|---|
| License | $20.90M |
| Consulting Services | $7.70M |
| Total | $28.60M |
Zevra Therapeutics brought in $28.60M from its two product and service lines in fiscal 2021, the year ended December 31, 2021. License was the largest at $20.90M (73.1%), ahead of Consulting Services at $7.70M (26.9%).
Previously Reported was Zevra Therapeutics’s largest revenue line in fiscal 2023, bringing in $14.24M of $17.14M (83%).
| Revision of Prior Period | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2023 |
|---|---|---|---|---|---|---|
| Previously Reported | $5.27M | $8.14M | $10.46M | $2.88M | $8.47M | $14.24M |
| As Restated | — | — | — | — | $8.47M | $2.90M |
| Revision Of Prior Period, Error Correction, Adjustment | -$48.00K | -$123.00K | — | $297.00K | — | — |
| Total | $5.22M | $8.02M | $10.46M | $3.18M | $16.94M | $17.14M |
Zevra Therapeutics brought in $17.14M from its two revenue lines in fiscal 2023, the year ended September 30, 2023. That was up 1.2% from $16.94M in fiscal 2023. Previously Reported was the largest at $14.24M (83.1%), ahead of As Restated at $2.90M (16.9%).
Compared with fiscal 2023, Previously Reported grew 68.2% to $14.24M, while As Restated fell 65.8% to $2.90M.
Zevra Therapeutics began breaking out As Restated in fiscal 2023, when it brought in $8.47M. Zevra Therapeutics stopped reporting Revision Of Prior Period, Error Correction, Adjustment as a separate revenue line after fiscal 2023, when it brought in $297.00K.
Zevra Therapeutics (ZVRA) reports its revenue by product and service and by revision of prior period. In fiscal 2021, Aquestive Therapeutics was its largest product and service line, bringing in $20.90M (73.1% of the total), followed by Corium, Inc at $7.70M (26.9%).
Aquestive Therapeutics was Zevra Therapeutics' largest product and service line in fiscal 2021, bringing in $20.90M, or 73.1% of the $28.60M total across its two product and service lines.
Previously Reported was Zevra Therapeutics' largest revenue line in fiscal 2023, bringing in $14.24M, or 83.1% of the $17.14M total across its two revenue lines.
Every figure comes from Zevra Therapeutics' annual financial filings, as reported. Each line keeps the name Zevra Therapeutics gives it, and years follow its fiscal calendar.
Zevra Therapeutics' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2021. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.